The Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) drugs in development market research report provides comprehensive information on the therapeutics under development for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) and features dormant and discontinued products.

GlobalData tracks 23 drugs in development for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) by 21 companies/universities/institutes. The top development phase for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) is phase ii with 12 drugs in that stage. The Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline has 21 drugs in development by companies and two by universities/ institutes. Some of the companies in the Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline products market are: F. Hoffmann-La Roche, Bristol-Myers Squibb and Daiichi Sankyo.

The key targets in the Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline products market include Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1), Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1), and ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1).

The key mechanisms of action in the Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline product include Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Inhibitor with three drugs in Phase II. The Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline products include 11 routes of administration with the top ROA being Oral and six key molecule types in the Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline products market including Small Molecule, and Monoclonal Antibody.

Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) overview

Leptomeningeal carcinomatosis is a condition involving the infiltration of cancer into the protective layers of the brain, specifically the pia mater and arachnoid mater. Solid tumors, notably breast, lung, melanoma, gastrointestinal, and primary central nervous system tumors, can give rise to leptomeningeal carcinomatosis. Cancer cells may reach the leptomeninges through various routes, such as direct seeding from brain parenchyma, dura mater (not shielded by the blood-brain barrier), bone, endoneurial/perineural invasion, and hematogenous seeding. Symptoms, initially nonspecific, encompass cerebral manifestations like headaches and confusion, posterior fossa indicators such as cranial nerve deficits, vascular complications, spinal cord issues, and inflammatory reactions causing disruptions in CSF flow. Diagnosing leptomeningeal carcinomatosis is challenging due to the low sensitivity of diagnostic tools, necessitating a comprehensive evaluation involving high-quality MRI scans and CSF studies.

For a complete picture of Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.